These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 20825627)

  • 1. The modeled lifetime cost-effectiveness of published adherence-improving interventions for antihypertensive and lipid-lowering medications.
    Chapman RH; Kowal SL; Cherry SB; Ferrufino CP; Roberts CS; Chen L
    Value Health; 2010; 13(6):685-94. PubMed ID: 20825627
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The cost and effectiveness of adherence-improving interventions for antihypertensive and lipid-lowering drugs*.
    Chapman RH; Ferrufino CP; Kowal SL; Classi P; Roberts CS
    Int J Clin Pract; 2010 Jan; 64(2):169-81. PubMed ID: 20089007
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The clinical and economic burden of nonadherence with antihypertensive and lipid-lowering therapy in hypertensive patients.
    Cherry SB; Benner JS; Hussein MA; Tang SS; Nichol MB
    Value Health; 2009 Jun; 12(4):489-97. PubMed ID: 18783393
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The clinical and economic burden of poor adherence and persistence with osteoporosis medications in Ireland.
    Hiligsmann M; McGowan B; Bennett K; Barry M; Reginster JY
    Value Health; 2012; 15(5):604-12. PubMed ID: 22867768
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Results of a Markov model analysis to assess the cost-effectiveness of statin therapy for the primary prevention of cardiovascular disease in Korea: the Korean Individual-Microsimulation Model for Cardiovascular Health Interventions.
    Kang HY; Ko SK; Liew D
    Clin Ther; 2009 Dec; 31(12):2919-30; discussion 2916-8. PubMed ID: 20110032
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rational prescribing in primary care (RaPP): economic evaluation of an intervention to improve professional practice.
    Fretheim A; Aaserud M; Oxman AD
    PLoS Med; 2006 Jun; 3(6):e216. PubMed ID: 16737349
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of screening and optimal management for diabetes, hypertension, and chronic kidney disease: a modeled analysis.
    Howard K; White S; Salkeld G; McDonald S; Craig JC; Chadban S; Cass A
    Value Health; 2010; 13(2):196-208. PubMed ID: 19878493
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Cost-Effectiveness of Low-Cost Essential Antihypertensive Medicines for Hypertension Control in China: A Modelling Study.
    Gu D; He J; Coxson PG; Rasmussen PW; Huang C; Thanataveerat A; Tzong KY; Xiong J; Wang M; Zhao D; Goldman L; Moran AE
    PLoS Med; 2015 Aug; 12(8):e1001860. PubMed ID: 26241895
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost effectiveness of coronary heart disease prevention strategies in adults.
    Brown AD; Garber AM
    Pharmacoeconomics; 1998 Jul; 14(1):27-48. PubMed ID: 10182193
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of the Medicare Part D coverage gap on medication use among patients with hypertension and hyperlipidemia.
    Li P; McElligott S; Bergquist H; Schwartz JS; Doshi JA
    Ann Intern Med; 2012 Jun; 156(11):776-84, W-263, W-264, W-265, W-266, W-267, W-268, W-269. PubMed ID: 22665815
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The (cost-)effectiveness of a patient-tailored intervention programme to enhance adherence to antihypertensive medication in community pharmacies: study protocol of a randomised controlled trial.
    van der Laan DM; Elders PJ; Boons CC; Bosmans JE; Nijpels G; Hugtenburg JG
    Trials; 2017 Jan; 18(1):29. PubMed ID: 28103948
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improving adherence to lipid-lowering therapy in a community pharmacy intervention program: a cost-effectiveness analysis.
    Vegter S; Oosterhof P; van Boven JF; Stuurman-Bieze AG; Hiddink EG; Postma MJ
    J Manag Care Spec Pharm; 2014 Jul; 20(7):722-32. PubMed ID: 24967525
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost effectiveness of prostacyclins in pulmonary arterial hypertension.
    Roman A; Barberà JA; Escribano P; Sala ML; Febrer L; Oyagüez I; Sabater E; Casado MA
    Appl Health Econ Health Policy; 2012 May; 10(3):175-88. PubMed ID: 22452448
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of osteoporosis screening followed by treatment: the impact of medication adherence.
    Hiligsmann M; Gathon HJ; Bruyère O; Ethgen O; Rabenda V; Reginster JY
    Value Health; 2010; 13(4):394-401. PubMed ID: 20102558
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of enhancing adherence to therapy with blood pressure-lowering drugs in the setting of primary cardiovascular prevention.
    Scotti L; Baio G; Merlino L; Cesana G; Mancia G; Corrao G
    Value Health; 2013; 16(2):318-24. PubMed ID: 23538184
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Economic and health effect of full adherence to controller therapy in adults with uncontrolled asthma: a simulation study.
    Zafari Z; Lynd LD; FitzGerald JM; Sadatsafavi M
    J Allergy Clin Immunol; 2014 Oct; 134(4):908-915.e3. PubMed ID: 24875619
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The cost-effectiveness of routine office-based identification and subsequent medical treatment of primary open-angle glaucoma in the United States.
    Rein DB; Wittenborn JS; Lee PP; Wirth KE; Sorensen SW; Hoerger TJ; Saaddine JB
    Ophthalmology; 2009 May; 116(5):823-32. PubMed ID: 19285730
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness analysis of valsartan versus losartan and the effect of switching.
    Baker TM; Goh J; Johnston A; Falvey H; Brede Y; Brown RE
    J Med Econ; 2012; 15(2):253-60. PubMed ID: 22084957
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of renin-guided treatment of hypertension.
    Smith SM; Campbell JD
    Am J Hypertens; 2013 Nov; 26(11):1303-10. PubMed ID: 24048147
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-Utility of an Objective Biochemical Measure to Improve Adherence to Antihypertensive Treatment.
    van Schoonhoven AV; van Asselt ADI; Tomaszewski M; Patel P; Khunti K; Gupta P; Postma MJ
    Hypertension; 2018 Nov; 72(5):1117-1124. PubMed ID: 30354817
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.